Effects of Gabapentinoids on Chronic Low Back Pain: A Study Overview

Introduction to Chronic Low Back Pain

Chronic low back pain is a common condition affecting many individuals, often characterized by its nonspecific nature. It is recognized as the leading cause of years lived with disability among chronic health issues.

Gabapentinoids: Gabapentin and Pregabalin

Gabapentin (GB) and Pregabalin (PG) are medications classified as gabapentinoids, primarily effective in treating neuropathic pain conditions. Despite the absence of a strong justification, the utilization of gabapentinoids for chronic low back pain has notably increased in recent years.

Recent Meta-Analysis Findings

A recent meta-analysis published in PLoS Medicine aimed to evaluate the effectiveness of gabapentinoids in alleviating pain and enhancing functionality in patients with chronic low back pain, as well as identifying potential adverse effects.

Research Methodology

The study involved a comprehensive search of electronic databases, including MEDLINE and EMBASE, up to December 20, 2016. The researchers focused on randomized controlled trials involving adult patients suffering from chronic low back pain for more than three months. Data extraction and study selection were conducted independently by paired reviewers.

Outcome Measures and Evidence Quality Assessment

Outcomes were aligned with the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials guidelines, emphasizing pain relief and safety as primary outcomes. The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework was employed to evaluate the quality of evidence.

Study Selection and Analysis

From an initial pool of 1,385 citations, only eight randomized controlled trials met the inclusion criteria. The trials were categorized into three groups: GB versus placebo, PG versus other analgesics, and PG as an adjuvant therapy.

Results of the Comparisons

The three studies comparing GB with placebo indicated only minimal pain relief. In contrast, studies comparing PG with alternative analgesics showed more significant improvements in pain management. The trials assessing PG as an adjunct therapy could not be pooled due to substantial methodological differences, but the largest study indicated no advantage of adding PG to tapentadol.

Adverse Effects and Evidence Quality

No deaths or hospitalizations were reported during the studies. However, GB was associated with a higher incidence of adverse events such as dizziness, fatigue, cognitive difficulties, and visual disturbances compared to placebo. The GRADE assessment revealed very low evidence quality for dizziness and fatigue, low for cognitive difficulties, and moderate for visual disturbances.

Conclusions and Recommendations

Overall, the evidence suggests that the use of gabapentinoids, particularly GB, carries an increased risk of adverse effects while providing only minimal benefits. The authors advise caution in considering gabapentinoids for chronic low back pain management.

Reference

Shanthanna H, Gilron I, Rajarathinam M, AlAmri R, Kamath S, et al. (2017) Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. PLOS Medicine 14(8): e1002369. https://doi.org/10.1371/journal.pmed.1002369